- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy. (On Demand | Level 1, West Hall; Poster Board No. P4) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_925;
This is the first trial exploring autophagy modulation in advanced, BRAF-mutated colon cancer. This study aims to show that autophagy inhibition with HCQ circumvents acquired resistance to BRAF + EGFR inhibition in advanced colon cancer.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
The role of gene expression of CDC37 in colorectal cancer (CRC). (On Demand | Level 1, West Hall; Poster Board No. M19) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_900;
Our results support the kinase-stabilizing function of CDC37 in CRC. Further investigations combined with survival data are warranted to address the prognostic and predictive values of CDC37 expression in targeted therapies of CRC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). (On Demand | Level 1, West Hall; Poster Board No. F16) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_783;
P2, P3
In the phase 2 ANCHOR study (NCT03693170), mPFS was 5.8 mo and ORR was 48% for 1L EC + binimetinib in BRAFV600E mCRC...Pts received E 300 mg daily + C 500 mg/m2 every 2 weeks (Q2W) + either mFOLFOX6 Q2W (n=27) or FOLFIRI Q2W (n=30) in 28-day cycles until disease progression or unacceptable toxicity...Expected conclusions will be included in the final abstract. Clinical trial information: NCT04607421.
- |||||||||| Tagrisso (osimertinib) / AstraZeneca
Journal, BRCA Biomarker: Combination treatment of arsenic trioxide and osimertinib in recurrent and metastatic head and neck squamous cell carcinoma. (Pubmed Central) - Dec 13, 2022
Additionally, ATO/AZD decreases the expression and activity of breast cancer type 1 susceptibility protein (BRCA1) and polo-like kinase 1 (PLK1), thereby impairing Rad51 recruitment to DNA double-strand lesion for repair and may ultimately cause tumor cell death. In conclusion, this study provides a concrete experience and an alternate strategy of ATO/AZD therapy for patients with R/M HNSCC.
- |||||||||| divarasib (RG6330) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (clinicaltrials.gov) - Dec 13, 2022
P1a/1b, N=498, Recruiting,
In conclusion, this study provides a concrete experience and an alternate strategy of ATO/AZD therapy for patients with R/M HNSCC. Trial completion date: Aug 2023 --> Nov 2024 | Trial primary completion date: Aug 2023 --> Nov 2024
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Turning antibodies off and on again using a covalently tethered blocking peptide. (Pubmed Central) - Dec 12, 2022
We demonstrate that protease-cleavable and photocleavable moieties in the tether enable controlled antibody activation to the "on-state" for anti-FLAG and cetuximab antibodies. Protein L can bind a range of antibodies used therapeutically and in research for wide applicability.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal: An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer. (Pubmed Central) - Dec 12, 2022
Targeted therapy based on the use of anti-epidermal growth factor receptors (EGFRs) is conditioned by the potential for increased toxicity, making it more difficult to treat an older, rat sarcoma virus (RAS) and B rapidly accelerated fibrosarcoma (BRAF) wild-type patient. In light of a more detailed characterization of the older population, modernly differentiable between fit, vulnerable, or frail patients on the basis of the comprehensive geriatric assessment, and of the analysis of more recent studies, this review fully collects data from the literature, differentiating the results on functional status patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, sEphB4-HSA / VasGene, National Cancer Institute
Trial completion, Combination therapy, Metastases: sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC (clinicaltrials.gov) - Dec 12, 2022
P1, N=3, Completed,
In light of a more detailed characterization of the older population, modernly differentiable between fit, vulnerable, or frail patients on the basis of the comprehensive geriatric assessment, and of the analysis of more recent studies, this review fully collects data from the literature, differentiating the results on functional status patients. Active, not recruiting --> Completed
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Surgery, Metastases: SWOG S1613: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 7, 2022
P2, N=240, Active, not recruiting,
Active, not recruiting --> Completed Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Retrospective data, Journal: Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study. (Pubmed Central) - Dec 6, 2022
More importantly, in this study although KRAS mutations were detected in two clinical cases, evident tumor inhibition was still observed after cetuximab treatment in both PDX models and patients...The relationship between clinicopathological and molecular features and engraftment rates were clarified. Furthermore, this resource provides us with profound insights into tumor heterogeneity, making these models valuable for PDX-guided treatment decisions, and offering the PDX model as a great tool for personalized treatment and translation research.
- |||||||||| CIML NK - Dana / Farber Cancer Institute
Trial completion date, Trial primary completion date, Combination therapy, Metastases, Immune cell: CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) - Dec 6, 2022
P1, N=12, Recruiting,
Taken together, our data suggest that Cetuximab exerts potential anti-cancer activities in FOSCC, paving the way for future translational studies aimed at assessing its employment in the therapy of this lethal cancer of cats. Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
- |||||||||| Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer (clinicaltrials.gov) - Dec 5, 2022
P2, N=59, Recruiting,
Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment closed, Combination therapy, Metastases: Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Dec 5, 2022
P1, N=20, Active, not recruiting,
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Active, not recruiting
- |||||||||| Preclinical, Journal, IO biomarker: Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies. (Pubmed Central) - Dec 3, 2022
MTT assay, gene expression analysis (BAX, BCL-2, and β-catenin), apoptosis analysis, TEM, cell cycle assay, ELISA, and cell migration assays were conducted to perform the cell death analysis of lung cancer and breast cancer, compared to the marketed product. The MTT assay exhibited 80% cell death for 75 µM and 100µM; however, flow cytometry analysis with the IC value demonstrated that the selected compound induced higher apoptosis in MCF-7 (30.8%) than in A549.
- |||||||||| TTX-080 / Tizona Therap
Trial primary completion date, Combination therapy, Monotherapy, Metastases: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov) - Dec 2, 2022
P1a/1b, N=240, Recruiting,
The real-life beneficial evidence of the combination is consistent with the results documented in the randomized controlled trials. Trial primary completion date: Dec 2022 --> Jun 2023
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. (Pubmed Central) - Dec 2, 2022
Indeed, therapies targeting EGFR, particularly cetuximab-DM1, demonstrated a strong anti-proliferative action on cells with acquired resistance to T-DM1 and HER2 loss. The expression of EGFR in cells resistant to T-DM1 offers the possibility of using therapies directed to this receptor to combat resistance to anti-HER2 drugs and loss of HER2 overexpression.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change: Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients (clinicaltrials.gov) - Dec 1, 2022
P2, N=24, Completed,
The expression of EGFR in cells resistant to T-DM1 offers the possibility of using therapies directed to this receptor to combat resistance to anti-HER2 drugs and loss of HER2 overexpression. Recruiting --> Completed | N=100 --> 24
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: A glyco-engineering approach for site-specific conjugation to Fab glycans. (Pubmed Central) - Dec 1, 2022
We confirmed that these ADCs still bind their targets efficiently and are as potent in cytotoxicity assays as control ADCs obtained by standard conjugation protocols. The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
- |||||||||| ligufalimab (AK117) / Akesobio
Journal, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. (Pubmed Central) - Dec 1, 2022
AK117 eliminated hemagglutination and also enabled to maintain full effectiveness of CD47 blockade on tumor cells, which resulted in excellent antitumor efficacy and favorable safety profile of AK117. A series of clinical trials of AK117 as a therapeutic agent in combination with various agents such as AK112 are in progress for the treatment of multiple hematologic malignancies and solid tumors.
- |||||||||| vinorelbine tartrate / Generic mfg.
Mapk inhibition in combination with vinorelbine might represent a new therapeutical option for brafv600e CRC () - Nov 30, 2022 - Abstract #DKK2022DKK_2119;
Moreover, ten BRAFV600E CRC PDOs were treated with single agent VBN; PDOs with higher VBN IC50 were treated with VBN in combination with erlotinib (OSI-774) + LGX818.The expression of pEGFR, pAKT, pERK, P-glycoprotein and cleaved PARP was tested both in cell lines and PDOs after 24, 48, and 72h... The triple combination represents a promising treatment option for BRAFV600E mCRC patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Impact of standard therapy on immune checkpoint regulation in 2D and 3D HNSCC models (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_1906;
Irradiation (IR) alone and in combination with cisplatin or cetuximab was applied to a HNSCC 2D cell culture model. Our findings suggest a complex and probably context-dependent PD-L1 regulation upon application of radiochemotherapy and further experimental and (pre-)clinical analyses will be essential to unravel underlying molecular principles.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: a multi-centric, multi-national, prospective, non-interventional study in Germany, Austria and Switzerland – BERING CRC (Room A2) - Nov 30, 2022 - Abstract #DKK2022DKK_1858;
The study design and current enrollment status will be presented. Indication of source: 1 Koeberle D. et al., DGHO congress 2021, abstract #75
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Hematological and Solid Tumour Malignancies () - Nov 29, 2022 - Abstract #ASH2022ASH_7778;
Overall, we provide a proof of concept that allogeneic, in-house Fcγ-CR-T cells derived from a non-pathogenic viral backbone such as the FV, could be a safe, efficient and affordable alternative to LV-derived vectors for immunotherapy. Our future aim is to further modify these Fcγ-CR-T cells, by interfering with immune checkpoint molecules, in order to achieve better tumour penetration and tackle the anergy induced by the tumour microenvironment.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer. (Pubmed Central) - Nov 27, 2022
NIR-PIT for head and neck cancer (HN-PIT) is expected to provide a curative treatment option for the locoregional recurrent or metastatic disease after radiotherapy and surgery. This article reviews the mechanism underlying the effect of NIR-PIT and recent clinical trials of NIR-PIT for head and neck cancers, treatment-specific adverse events, combination treatment with immune checkpoint inhibitors, illumination approach and posttreatment quality of life, and provides a case of series of two patients who receive NIR-PIT for oropharyngeal cancer at our institution.
|
